We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Bispebjerg Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00259168
First Posted: November 29, 2005
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Novartis
Bayer
Information provided by:
Bispebjerg Hospital
  Purpose
The purpose of this study is to determine whether attenuation/normalization of elevated blood sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin resistance.

Condition Intervention Phase
Insulin Resistance Impaired Fasting Glucose Drug: Nateglinide Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Insulin Resistance and Postprandial Endothelial Function: Does Early Intervention Make a Difference?

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • Endothelial function

Secondary Outcome Measures:
  • Metabolic function

Estimated Enrollment: 70
Study Start Date: June 2003
Detailed Description:

Background:Insulin Resistance (IR) is accompanied by a high incidence and prevalence of cardiovascular disease. IR is present in individuals with pre-diabetes/ type 2 diabetes. Epidemiological data demonstrate a tight relationship between postprandial blood sugar, insulin resistance and cardiovascular disease (CVD). Endothelial dysfunction seems to be the very first sign of CVD.

Purpose: We propose to determine whether attenuation /normalization of post-prandial hyperglycaemia, through the administration of an oral hypoglycaemic agent of ultra rapid action (nateglinide), ameliorates endothelial function in the IR.

We extrapolate that a better endothelial function in the brachial artery reflects regression of atherosclerotic changes in the coronary system.

Method and Study Design: Prospective, open, parallel, group comparison study of 1 intervention group, 1 intervention control group and 1 disease control group. The intervention group and the intervention control group each consist of 30 individuals with IR. Individuals in the intervention group receive an individually adjusted dose of nateglinide 3 times daily during 12 weeks. The third group consists of 10 healthy, young individuals. All groups are followed during 3 months with an otherwise unchanged lifestyle. Endothelial function is measured with the Flow Mediated Dilation method before and after the intervention/observation period.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Insulin resistance, impaired glucose tolerance

Exclusion Criteria:

  • unstable chronic disease, acute disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00259168


Contacts
Contact: Atheline Major-Pedersen, MD 35316160 atmp@heart.dk

Locations
Denmark
Endothelial laboratory, Cardiology clinic Y-research, H:S Bispebjerg Hospital Recruiting
Bispebjerg Bakke, Copenhagen, Copenhagen NV, Denmark, 2400
Contact: Atheline Major-Pedersen, MD    35316160    atmp@heart.dk   
Contact: Christian Torp-Pedersen, MD, DMSc    35316159    ctp@heart.dk   
Principal Investigator: Atheline Major-Pedersen, MD         
Sub-Investigator: Nikolaj Ihlemann, MD, Phd         
Sub-Investigator: Thomas S Hermann, MD         
Sub-Investigator: Helena Dominguez, MD, Phd         
Sub-Investigator: Britt Kveiborg, MD         
Sub-Investigator: Buris Christiansen         
Sub-Investigator: Christian Rask-Madsen, MD, Phd         
Sub-Investigator: Ole L Svendsen, MD, DMSc         
Sub-Investigator: Lars Køber, MD, DMsc         
Sub-Investigator: Dorthe B Braunberg, Lab tech.         
Sub-Investigator: Christian Torp-Pedersen, MD, DMSc         
Sponsors and Collaborators
Bispebjerg Hospital
Novartis
Bayer
Investigators
Study Chair: Christian Torp-Pedersen, MD, DMSc Bispebjerg Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00259168     History of Changes
Other Study ID Numbers: 02-005/03
First Submitted: November 28, 2005
First Posted: November 29, 2005
Last Update Posted: December 9, 2005
Last Verified: November 2005

Keywords provided by Bispebjerg Hospital:
Postprandial endothelial function

Additional relevant MeSH terms:
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Nateglinide
Hypoglycemic Agents
Physiological Effects of Drugs